Mozart Therapeutics Publishes MTX-101 Preclinical Data Showing CD8 T Cell Network Modulation for Immune Balance

15 November 2024
Mozart Therapeutics, a clinical-stage biopharmaceutical company based in Seattle, announced the publication of its first peer-reviewed article in the journal Frontiers in Immunology. Titled "Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases," this paper highlights the preclinical findings on MTX-101, a new bispecific antibody. This research builds on previous work that identified a subset of cytolytic CD8 T cells (known as CD8 Treg) with anti-inflammatory effects, which are often dysfunctional in autoimmune diseases.

The study provides detailed insights into the mechanisms behind CD8 Treg dysfunction and how MTX-101 can potentially restore these cells' functions. MTX-101 has been shown to selectively bind to human CD8 Treg cells, effectively restoring their cytolytic activity. This leads to the elimination of pathogenic CD4 T cells in both peripheral and disease-affected tissues. Notably, the research indicates that MTX-101 does not broadly suppress the immune system or impair responses to viral and bacterial antigens, suggesting a targeted therapeutic potential.

Courtney Crane, Ph.D., Senior Vice President of Biology and Translational Medicine at Mozart Therapeutics, emphasized the significance of this publication. Crane noted that the paper reflects the dedication of the Mozart Therapeutics team to developing innovative treatments for autoimmune diseases. The preclinical data supports the ongoing clinical development of MTX-101 and confirms its broad therapeutic potential in early-stage and indolent autoimmune diseases.

The publication is particularly timely as Mozart Therapeutics is currently conducting a Phase 1 clinical study to evaluate MTX-101. This study involves both healthy adults and patients with type 1 diabetes (T1D) and celiac disease. The company is committed to advancing its understanding of CD8 Treg dysfunctions and developing therapeutic molecules that offer effective and sustainable solutions for autoimmune conditions.

MTX-101 is designed as a bispecific antibody that targets inhibitory KIR and CD8 expressed on regulatory CD8 T cells. This autoimmune checkpoint inhibitor aims to restore the natural functions of regulatory CD8 T cells early in the autoimmune disease process. By doing so, it seeks to suppress and eliminate pathogenic cells, halt subsequent inflammation, and prevent tissue damage. The ongoing clinical trial, which is randomized, blinded, and placebo-controlled, is assessing the safety, pharmacokinetics, and pharmacodynamics of MTX-101. For patients with type 1 diabetes or celiac disease, disease-specific biomarkers are also being evaluated.

Mozart Therapeutics is dedicated to developing first-in-class disease-modifying therapies for autoimmune diseases. Their novel approach focuses on restoring immune system function by targeting the CD8 T regulatory network. The company's mission is to offer innovative treatments that address the underlying mechanisms of autoimmunity, thereby providing lasting benefits to patients.

In summary, the publication of Mozart Therapeutics' first peer-reviewed article is a milestone that underscores the company's commitment to advancing autoimmune disease treatments. The preclinical data on MTX-101 lays a strong foundation for its ongoing clinical evaluation and highlights its potential as a targeted therapeutic option. With a focus on innovative therapies, Mozart Therapeutics aims to make significant strides in the field of autoimmune disease treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!